Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Shares Outstanding (2020 - 2025)

Journey Medical (DERM) has disclosed Shares Outstanding for 6 consecutive years, with $20.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 239.54% year-over-year to $20.4 million, compared with a TTM value of $20.4 million through Sep 2025, up 239.54%, and an annual FY2024 reading of $6.0 million, down 54.97% over the prior year.
  • Shares Outstanding was $6.0 million for Q3 2025 at Journey Medical, roughly flat from $6.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $16.2 million in Q4 2024 and bottomed at $6.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $7.4 million, with a median of $6.0 million recorded in 2021.
  • Peak annual rise in Shares Outstanding hit 239.54% in 2025, while the deepest fall reached 57.2% in 2025.
  • Year by year, Shares Outstanding stood at $6.0 million in 2021, then changed by 0.0% to $6.0 million in 2022, then surged by 122.07% to $13.3 million in 2023, then plummeted by 54.97% to $6.0 million in 2024, then soared by 239.54% to $20.4 million in 2025.
  • Business Quant data shows Shares Outstanding for DERM at $20.4 million in Q3 2025, $6.0 million in Q2 2025, and $6.0 million in Q1 2025.